Get started
Work

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells

Year: 2015
Type: article
Abstract: Meeting abstracts Anti-CD19 chimeric antigen receptor T cells (CART19) and bi-specific anti-CD19/CD3 antibodies (blinatumomab) are generating unprecedented complete responses in relapsing/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, a subset of patients still relapse and
DOI: 10.1186/2051-1426-3-s2-o5
Authors: Marco Ruella, David M Barrett, Saad S Kenderian, Olga Shestova, Ted J Hofmann, John Scholler, Simon F Lacey, Jan J Melenhorst, Farzana Nazimuddin, Jessica Perazzelli, David A Christian, Christopher A Hunter, David L Porter, Carl H June, Stephan A Grupp, Saar Gill
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W1960908689
FWCI: 0.391
Cites: 5
Cited by: 6
Related to: 10